Drug Type Biosimilar, Hormone |
Synonyms Recombinant Human Growth Hormone, Recombinant somatropin (Changchun Genescience), 重组人生长激素(金赛药业) + [3] |
Target |
Mechanism GHR agonists(Growth hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1998), |
RegulationPriority Review (CN) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Recombinant human growth hormone(Changchun Genescience) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Short Stature, Idiopathic, Autosomal | CN | 04 Aug 2022 | |
Noonan Syndrome | CN | 27 Jun 2017 | |
Burns | CN | 01 Jan 1998 | |
Growth Disorders | CN | 01 Jan 1998 | |
Growth hormone deficiency | CN | 01 Jan 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prader-Willi Syndrome | NDA/BLA | CN | 15 Oct 2020 | |
Chronic Kidney Diseases | Phase 3 | CN | 25 Jun 2018 | |
Idiopathic short stature | Phase 3 | CN | 11 Jun 2018 |
NCT03635580 (Pubmed) Manual | Phase 3 | 481 | vpsbbuohhj(kaxwcaoryl) = hiegcdggws avwohjgxpr (qkrzrjkeud, 0.31) View more | Positive | 29 Apr 2022 | ||
no treatment | vpsbbuohhj(kaxwcaoryl) = dykwepojzw avwohjgxpr (qkrzrjkeud, 0.33) View more |